- Home
- CRBP vs SDA Comparison
CRBP vs SDA Comparison
Compare CRBP & SDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | SDA |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.6M | 213.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CRBP | SDA |
|---|---|---|
| Price | $9.69 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $50.29 | $4.75 |
| AVG Volume (30 Days) | ★ 513.0K | 83.5K |
| Earning Date | 11-12-2025 | 10-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $461,120,000.00 |
| Revenue This Year | N/A | $10.86 |
| Revenue Next Year | $100.00 | $13.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.17 |
| 52 Week Low | $4.64 | $1.54 |
| 52 Week High | $20.56 | $10.61 |
Technical Indicators
Market Signals| Indicator | CRBP | SDA |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 41.27 |
| Support Level | $9.44 | $1.83 |
| Resistance Level | $11.64 | $2.18 |
| Average True Range (ATR) | 0.74 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 12.16 | 17.08 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.